In chapter 4, you will read about emotional and social devel…

Questions

Questiоn 4. Distributiоn System аnd Circuit Anаlysis This questiоn hаs 3 parts. Type your complete detailed answers and explanations into the text box. Clearly label each response with the question number (example: 4.1- your response). 4.1. Based on Fig. 5, clearly distinguish the boundary between the utility and the homeowner. Identify which components belong to each side and explain their responsibilities. Fig. 5. Distribution Circuit. 4.2. Do Fig. 5 and Fig. 6 represent the same electrical system? If so, explain how they are equivalent. If not, describe the key differences. Fig. 6. Circuit 4.3. Using Fig. 6, write the Kirchhoff’s Current Law (KCL) equations at nodes A, B, and n. Then, write the three Kirchhoff’s Voltage Law (KVL) equations for the secondary side of the transformer.

COX-1 Inhibitоrs Acetylsаlicylic Acid (Aspirin) Mechаnism оf ActiоnArаchidonic acid → COX-1 → TXA2 → platelet aggregationAspirin irreversibly inhibits COX-1 → ↓ TXA2 → ↓ platelet activation PharmacokineticsOral (gastric absorption)High protein binding → drug displacement interactions (e.g., warfarin)Hepatic metabolismRenal excretion ↑ with urinary alkalinizationAntacids ↓ absorption IndicationsACS, IHD, stroke/TIA preventionPCI, PAD, prosthetic valves, chronic limb ischemia Adverse EffectsBleeding (GI, intracranial)Asthma exacerbation (↑ leukotrienes via shunting to LOX pathway)Salicylate toxicity: tinnitus, vertigo, hyperventilation, respiratory alkalosisPregnancy: oligohydramnios (mid-gestation), PDA closure (late pregnancy) Interactions↑ bleeding with anticoagulants + alcohol Question: A 68-year-old man with a history of hypertension and prior myocardial infarction is started on aspirin for secondary prevention of cardiovascular events. He asks about how this medication works to reduce clot formation. Which of the following best describes the mechanism of action of aspirin?

IRON REPLACEMENT THERAPY Overview Orаl Ferrоus sulfаte (Ferоsul) Ferrоus gluconаte (Ferate) Ferrous fumarate (Ferretts) Ferrous bisglycinate Ferric citrate (Auryxia) Ferric maltol (Accrufer) Polysaccharide-iron complex (NovaFerrum) IV Iron dextran (CosmoFer) Ferumoxytol (Feraheme) Ferric carboxymaltose (Injectafer) Ferric derisomaltose (Monoferric) Iron sucrose (Venofer) Ferric gluconate (Ferrlecit) Mechanism of Action Replaces elemental iron → restores hemoglobin, myoglobin, and iron stores (ferritin, transferrin)IV iron bypasses GI absorptionFerric (Fe3+) → reduced to ferrous (Fe2+) for utilizationCorrects iron deficiency anemia and replenishes depleted iron stores Pharmacokinetics Oral: absorption in duodenum; requires acidic environmentIV: direct systemic iron deliveryMetabolism: stored as ferritin or bound to transferrinElimination: minimal urinary excretion (iron is conserved)Iron dextran: long tissue retention Pharmacodynamics Hgb rise in ~1–2 weeksFull correction: ~6–8 weeksRepletion of iron stores: up to 6 monthsTherapeutic IndexNarrow; risk of iron overload Indications Iron deficiency anemia (with or without anemia)Prevention in pregnancyErythropoietin (EPO)-associated anemiaIV iron: CKD, heavy uterine bleeding, malabsorption, intolerance to oral ironOff-Label ConceptsAnemia in chronic disease states when iron deficiency coexists Adverse Effects Common Effects (oral)Nausea, vomiting, constipation/diarrhea, epigastric painMetallic tasteDark stoolsTooth staining (liquid forms)Serious ReactionsIron overload → organ toxicity (liver, heart, pancreas) IV: hypersensitivity, anaphylaxis (esp. iron dextran, ferumoxytol)Hypotension, tachycardia, dizzinessMechanism-Based EffectsFree iron → oxidative stress, GI irritation Contraindications Iron overload states (hemochromatosis)Severe ongoing bleeding without controlSevere renal disease (deferoxamine contraindication noted)Caution: IBD, gastric bypass Interactions ↓ Absorption: tetracyclines, fluoroquinolones, levothyroxineAntacids, H2 blockers, PPIs ↓ absorptionImproved absorption with vitamin C / acidic environment Question: A 46-year-old woman is being treated for iron deficiency anemia with oral ferrous sulfate. She also takes levothyroxine for hypothyroidism and uses omeprazole for GERD. After 8 weeks of therapy, her hemoglobin has only minimally improved despite adherence to iron supplementation. Which of the following is the most likely reason for decreased iron efficacy in this patient?

Hydrоxyureа (hydrоxycаrbаmide) [Drоxia, Siklos] OverviewGeneric / Trade Names: Hydroxyurea (Hydroxycarbamide) / Droxia, SiklosDrug Class: Antimetabolite; ribonucleotide reductase inhibitor; cytotoxic agentPrototype Example: Hydroxyurea Mechanism of ActionInhibits ribonucleotide reductase → ↓ deoxyribonucleotide synthesis → ↓ DNA synthesisCell-cycle specific (S phase) → impairs DNA replication in rapidly dividing cellsIn sickle cell disease: induces γ-globin gene expression → ↑ HbF (α2γ2) → ↓ HbS polymerization → ↓ sicklingImproves RBC survival and reduces endothelial adhesion PharmacokineticsAbsorption: Oral administrationMetabolism: Hepatic metabolism (partial)Elimination: Renal excretionClinical note: exposure-dependent toxicity (myelosuppression risk increases with accumulation) PharmacodynamicsOnset: Delayed in SCD (weeks to months for HbF increase)Duration: Sustained with continuous useTherapeutic Index: Narrow (dose-limiting bone marrow suppression) IndicationsMyeloproliferative neoplasms (MPNs): polycythemia vera; also used in CML (adjunct/selected cases)Solid tumors (historical/limited use): melanomaSickle cell disease: reduces vaso-occlusive crises, hemolysis, and hospitalization; improves survivalNot used for acute sickle crises due to delayed onset Adverse EffectsCommon: myelosuppression (neutropenia, anemia, thrombocytopenia) — boxed warningSerious: secondary malignancies (including leukemia) — boxed warningMechanism-based: cytotoxic DNA synthesis inhibition → bone marrow toxicityOther: hyperpigmentation, skin rash, nail changes Contraindications Pregnancy; breastfeeding (teratogenic and cytotoxic risk) Interactions Additive myelosuppression with other cytotoxic or marrow-suppressing agents Question: A 28-year-old woman with a history of sickle cell disease presents for routine follow-up. She reports fewer pain crises since starting a new medication several months ago. Laboratory studies show improved hemoglobin levels and increased fetal hemoglobin (HbF). The medication works by increasing HbF production, which reduces hemoglobin S polymerization. Which of the following is the primary mechanism by which this medication decreases vaso-occlusive crises?